Projects
Constrained tryptophan-based oligomers for intracellular and CNS drug delivery. Vrije Universiteit Brussel
Establishing Microfluidic Spatial Multidimensional Technology to Revolutionize the Post-genomic Discovery of Immunotherapeutic Strategies Enabling Novel Drug Development Vrije Universiteit Brussel
Multi-scale modelling of interstitial-to-lymphatic mass transport for the study of edema and trans-lymphatic drug administration Ghent University
We will develop a “multi-scale” model of interstitial-to-lymphatic mass transport, which mathematically describes transport processes at the smallest scale, while at the same time accounting for transport over
longer distances via the lymphatic vessels. The model will be set up and validated with experiments in rats. In the longer term, we will scale the model to the human lymphatic system.
Delay aversion in adolescent ADHD and the propensity for early drug use: a fMRI study. KU Leuven
Selection of bioactive quinoids and analysis of a combined drug therapie and immunoprophylaxis for the control of tuberculosis. University of Antwerp
Structure based design of TIMP1 binding PET tracer for Multiple Sclerosis. KU Leuven
Computational methods have been great assets saving time and resources in de novo design of new drug candidatures or diagnostic probers. In this doctoral project, two novel challenging targets will be tackled through following two parallel research tracks: one related to the treatment of cancer while the other to diagnosis of neurological disorders. Concerning the first research track, PKD2 is one of three isoforms of the protein kinase D ...
Fragment-based computational design of inhibitors of dipeptidyl peptidase 8 and 9. University of Antwerp
Rational design of biologics for therapeutic development (FoldCo) Ghent University
Thirty-six antibody-based biologics achieved blockbuster drug status (yearly sales exceeding a billion dollars) last year, and Humira alone generated $19.9 billion of global sales. Most biologics are monoclonal antibodies that, due to their extreme specificity, hold the promise to treat a variety of medical conditions for which no other treatments are currently available. Biologic drug development, however, still suffers from a high attrition ...
Structure-guided design of BK/JC virus capsid targeting antivirals KU Leuven
BK and JC viruses are closely related members of the polyomavirus family that latently infect 70-90% of humans and cause fatal clinical complications in immunocompromised patients (kidney failure and brain demyelination). There are no effective drugs to treat these infections. The lack of conventional, enzymatic antiviral targets such as proteases or integrases makes any development challeging. The small genome of polyomaviruses encodes two ...